299 related articles for article (PubMed ID: 27995550)
1. Somatic Mutations in Prostate Cancer: Closer to Personalized Medicine.
Alvarez-Cubero MJ; Martinez-Gonzalez LJ; Robles-Fernandez I; Martinez-Herrera J; Garcia-Rodriguez G; Pascual-Geler M; Cozar JM; Lorente JA
Mol Diagn Ther; 2017 Apr; 21(2):167-178. PubMed ID: 27995550
[TBL] [Abstract][Full Text] [Related]
2. Improving the genetic signature of prostate cancer, the somatic mutations.
Martinez-Gonzalez LJ; Pascual Geler M; Robles Fernandez I; Cozar JM; Lorente JA; Alvarez Cubero MJ
Urol Oncol; 2018 Jun; 36(6):312.e17-312.e23. PubMed ID: 29650325
[TBL] [Abstract][Full Text] [Related]
3. The mutational landscape of prostate cancer.
Barbieri CE; Bangma CH; Bjartell A; Catto JW; Culig Z; Grönberg H; Luo J; Visakorpi T; Rubin MA
Eur Urol; 2013 Oct; 64(4):567-76. PubMed ID: 23759327
[TBL] [Abstract][Full Text] [Related]
4. RAS mutations in human cancers: Roles in precision medicine.
Murugan AK; Grieco M; Tsuchida N
Semin Cancer Biol; 2019 Dec; 59():23-35. PubMed ID: 31255772
[TBL] [Abstract][Full Text] [Related]
5. Molecular genetics of prostate cancer: clinical translational opportunities.
Vecchione A; Gottardo F; Gomella LG; Wildemore B; Fassan Ms; Bragantini E; Pagano F; Baffa R
J Exp Clin Cancer Res; 2007 Mar; 26(1):25-37. PubMed ID: 17550130
[TBL] [Abstract][Full Text] [Related]
6. Integrating germline and somatic variation information using genomic data for the discovery of biomarkers in prostate cancer.
Mamidi TKK; Wu J; Hicks C
BMC Cancer; 2019 Mar; 19(1):229. PubMed ID: 30871495
[TBL] [Abstract][Full Text] [Related]
7. PI3K/AKT pathway regulates E-cadherin and Desmoglein 2 in aggressive prostate cancer.
Barber AG; Castillo-Martin M; Bonal DM; Jia AJ; Rybicki BA; Christiano AM; Cordon-Cardo C
Cancer Med; 2015 Aug; 4(8):1258-71. PubMed ID: 26033689
[TBL] [Abstract][Full Text] [Related]
8. Next-generation sequencing technology in prostate cancer diagnosis, prognosis, and personalized treatment.
Yadav SS; Li J; Lavery HJ; Yadav KK; Tewari AK
Urol Oncol; 2015 Jun; 33(6):267.e1-13. PubMed ID: 25791755
[TBL] [Abstract][Full Text] [Related]
9. Prostate cancer heterogeneity: Discovering novel molecular targets for therapy.
Ciccarese C; Massari F; Iacovelli R; Fiorentino M; Montironi R; Di Nunno V; Giunchi F; Brunelli M; Tortora G
Cancer Treat Rev; 2017 Mar; 54():68-73. PubMed ID: 28231559
[TBL] [Abstract][Full Text] [Related]
10. Molecular Updates in Prostate Cancer.
Netto GJ
Surg Pathol Clin; 2015 Dec; 8(4):561-80. PubMed ID: 26612215
[TBL] [Abstract][Full Text] [Related]
11. Epigenetics in prostate cancer: biologic and clinical relevance.
Jerónimo C; Bastian PJ; Bjartell A; Carbone GM; Catto JW; Clark SJ; Henrique R; Nelson WG; Shariat SF
Eur Urol; 2011 Oct; 60(4):753-66. PubMed ID: 21719191
[TBL] [Abstract][Full Text] [Related]
12. Roles of signaling pathways in drug resistance, cancer initiating cells and cancer progression and metastasis.
McCubrey JA; Abrams SL; Fitzgerald TL; Cocco L; Martelli AM; Montalto G; Cervello M; Scalisi A; Candido S; Libra M; Steelman LS
Adv Biol Regul; 2015 Jan; 57():75-101. PubMed ID: 25453219
[TBL] [Abstract][Full Text] [Related]
13. High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models.
Marques RB; Aghai A; de Ridder CMA; Stuurman D; Hoeben S; Boer A; Ellston RP; Barry ST; Davies BR; Trapman J; van Weerden WM
Eur Urol; 2015 Jun; 67(6):1177-1185. PubMed ID: 25220373
[TBL] [Abstract][Full Text] [Related]
14. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
[TBL] [Abstract][Full Text] [Related]
15. Genetic aspects of prostate cancer.
Latil A; Lidereau R
Virchows Arch; 1998 May; 432(5):389-406. PubMed ID: 9645438
[TBL] [Abstract][Full Text] [Related]
16. Genomic tests to guide prostate cancer management following diagnosis.
Colicchia M; Morlacco A; Cheville JC; Karnes RJ
Expert Rev Mol Diagn; 2017 Apr; 17(4):367-377. PubMed ID: 28277880
[TBL] [Abstract][Full Text] [Related]
17. Genetic testing for the clinician in prostate cancer.
López-Campos F; Linares-Espinós E; Maldonado Pijoan X; Sancho Pardo G; Morgan TM; Martínez-Ballesteros C; Martínez-Salamanca J; Couñago F
Expert Rev Mol Diagn; 2020 Sep; 20(9):933-946. PubMed ID: 32885704
[TBL] [Abstract][Full Text] [Related]
18. Genetic alterations in hepatocellular carcinoma: An update.
Niu ZS; Niu XJ; Wang WH
World J Gastroenterol; 2016 Nov; 22(41):9069-9095. PubMed ID: 27895396
[TBL] [Abstract][Full Text] [Related]
19. Role of lncRNAs in prostate cancer development and progression.
Weiss M; Plass C; Gerhauser C
Biol Chem; 2014 Nov; 395(11):1275-90. PubMed ID: 25153594
[TBL] [Abstract][Full Text] [Related]
20. Carcinoma of the prostate: inherited susceptibility, somatic gene defects and androgen receptors.
Montironi R; Scarpelli M; López Beltran A
Virchows Arch; 2004 Jun; 444(6):503-8. PubMed ID: 15045584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
